Vicore Pharma AB

Vicore Pharma is a clinical-stage pharmaceutical company with a focus on developing a new class of drugs with the potential to modify diseases. The company has a strong track record of collaboration with the scientific community, which has resulted in a wealth of preclinical data and ongoing clinical research in multiple indications. Their expertise lies in Angiotensin II Type 2 Receptor Agonists (ATRAGs), a unique class of drugs that stimulate the protective arm of the renin-angiotensin system (RAS), potentially reversing disease pathology.

Vicore is currently developing two main drug programs: Buloxibutid (C21) is a first-in-class orally available small molecule ATRAG currently in Phase 2a development for Idiopathic Pulmonary Fibrosis (IPF). Almee™ is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee™ has received Breakthrough Device Designation from the FDA, signifying its potential for transformative impact on patient care. Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company's shares (VICO) are listed on Nasdaq Stockholm's main market.

Vicore Pharma is a small and agile organization that values collaboration with its team members. While specific details about job flexibility are not provided in the job postings, the website describes the company as "highly experienced" and that they maintain "full control over the entire drug development chain", suggesting a team-oriented environment. This, in combination with the company's multiple locations, may indicate that there are opportunities for flexible work arrangements, but more information is needed for a definitive answer.

Vicore Pharma is an innovative clinical-stage pharmaceutical company committed to developing life-changing treatments for diseases where the AT2 (angiotensin II type 2) receptor plays a crucial role in halting and reversing disease pathology. Their focus is on unlocking the potential of a new class of drugs with disease-modifying potential, particularly in respiratory diseases like idiopathic pulmonary fibrosis (IPF). Vicore Pharma is driven by a dedication to finding holistic solutions for patients and their families, with a strong history of collaboration with the scientific community and ongoing clinical research in various indications to prove the AT2 receptor biology.

Vicore Pharma promotes a collaborative and agile culture, emphasizing close relationships with scientific and medical experts to ensure optimal drug development. They value a high level of experience within their team, spanning from early drug development to commercialization, and maintain full control over the entire drug development chain. This suggests a culture of expertise, innovation, and a dedication to achieving results.

Vicore Pharma does not explicitly state a company-wide approach to diversity, equity, and inclusion on their website.